Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Tivity Health, Inc. Oklahoma City, OK (November 22, 2017) – On November 20, 2017, a securities class action lawsuit was filed in the United States District Court for the Middle District of Tennessee against Tivity Health, Inc. (NASDAQ: TVTY). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Array Biopharma, Inc. Oklahoma City, OK (November 22, 2017) – On November 20, 2017, a securities class action lawsuit was filed in the United States District Court for the District of Colorado against Array Biopharma, Inc. (NASDAQ: ARRY). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against General Electric Company Oklahoma City, OK (November 8, 2017) – On November 1, 2017, a securities class action lawsuit was filed in the United States District Court for the Southern District of New York against General Electric Company (NYSE: GE). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Antares Pharma, Inc. Oklahoma City, OK (October 25, 2017) – On October 23, 2017, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Antares Pharma, Inc. (NASDAQ: ATRS). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Navient Corporation Oklahoma City, OK (October 18, 2017) – On October 16, 2017, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Navient Corporation (NASDAQ: NAVI). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Tesla, Inc. Oklahoma City, OK (October 11, 2017) – On October 10, 2017, a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Tesla, Inc. (NASDAQ: TSLA). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Health Insurance Innovations, Inc. Oklahoma City, OK (October 4, 2017) – On September 11, 2017, a securities class action lawsuit was filed in the United States District Court for the Eastern District of New York against Health Insurance Innovations, Inc. (NASDAQ: HIIQ). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price […]

To: All persons and/or entities who purchased common stock in Avalanche Biotechnologies, Inc. [AAVL] during the period between July 30, 2014 and June 15, and were damaged thereby; a settlement has been announced in the securities litigation known as In re: Avalanche Biotechnologies, Inc. Shareholder Litigation, CIV536488 (Superior Court of the State of Californioa, County of San Mateo) For additional information about this settlement, please see the Notice and Proof of Claim (links provided below): Notice of Pendency and Proposed Settlement of Class Action and Settlement Fairness Hearing; Proof of Claim and Release. Claim submission deadline is December 27, 2017. If you have any questions […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against SCANA Corporation Oklahoma City, OK (September 29, 2017) – On September 27, 2017, a securities class action lawsuit was filed in the United States District Court for the District of South Carolina against SCANA Corporation (NYSE: SCG). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which […]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Akari Therapeutics, Plc Oklahoma City, OK (May 15, 2017) – On May 12, 2017, a securities class action lawsuit was filed in the United States District Court for the Southern District of New York against Akari Therapeutics, Plc (NASDAQ: AKTX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the […]